Endogenous cannabinoid system: Ligands and receptors matched to transduction signals mechanism;Sistema cannabinoide endogeno: Ligandos y receptores acoplados a mecanismos de transduccion de senales

Adicciones

Volumn 12, Issue SUPPL. 2, 2000, Pages 59-81

  Ramos Atance, J A ^a   Fernandez Ruiz, J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Anandamide; Cannabis; Endocannabinoids; Neuromodulato rs; Neurotransmitters; Receptor

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM; CANNABINOID; CANNABINOID RECEPTOR; GLUTAMIC ACID; OPIATE AGONIST;

ADENOHYPOPHYSIS; BRAIN ISCHEMIA; BRAIN TOXICITY; CALCIUM TRANSPORT; HUMAN; LIGAND BINDING; MOTOR PERFORMANCE; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NOCICEPTION; RECEPTOR BINDING; RECEPTOR DENSITY; REVIEW; REWARD; SIGNAL TRANSDUCTION;

EID: 0033638141     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.672     Document Type: Review

References (115)

1. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A
2. Fatty acid amides of ethanolamine in mammalian tissues
3. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
4. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development
5. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period
6. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function
7. Microsomal cytochrome P-450-mediated liver and brain anandamide metabolism
8. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
9. Stimulation of cannabinoid receptor CB1 induces Krox-24 expression in human astrocytoma cells
10. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression
11. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor. 1. Evidence for a new model of receptor/ligand interactions
12. Regional differences in cannabinoid receptor/Gprotein coupling in rat brain
13. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor
14. Control of pain iniciation by endogenous cannabinoids
15. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist
16. D9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of concious, freely-moving rats as measured by intracerebral microdialysis
17. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
18. Functional significance of cannabinoid receptors in brain
19. Effects of cannabinoids on prolactin and gonadotrophin secretion: Involvement of changes in hypothalamic GABA inputs
20. Regulation of a neural form of focal adhesion kinase by anandamide
21. Determination and characterization of a cannabinoid receptor in rat brain
22. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
23. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
24. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
25. Cannabinoid agonists inhibit the activation of 5HT3 receptors in rat nodose ganglion neurons
26. Cannabinoid receptors and their endogenous agonists
27. Time-course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: Evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics
28. Role of endocannabinoids in brain development
29. The endogenous cannabinoid system and brain development
30. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
31. Isolation, structure, elucidation and partial synthesis of an active constituent of hashish
32. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor
33. Facilitation of brain stimulation reward by D9-tetrahydrocannabinol
34. Cannabinoid interaction with brain reward systems - The Neurobiological basis of cannabinoid abuse
35. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
36. The CB1 cannabinoid receptor antagonist SR141716A affects A9 dopamine neuronal activity in the rats
37. Effects of anandamide on hepatic fatty acid metabolism
38. Effects of cannabinoids on energy metabolism
39. Cannabinoids, hippocampal function and memory
40. Characterization of glutamate-induced formation of Nacylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons
41. Two new unsaturated fatty acids ethanolamides in brain that bind to the cannabinoid receptor
42. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
43. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat brain
44. D9-Tetrahydrocannabinol increases activity of tyrosing hydroxylase in cultured fetal mesencephalic neurons
45. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme
46. In vitro activation of brain protein kinase C by the cannabinoids
47. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilited diffusion
48. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6 q14-q15
49. Regulation of the cAMP cascade, gene expression and inmune function by cannabinoid receptors
50. Anandamide, an endogenous cannabinoid receptors ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor
51. Prolactin supression by (-)-D9-tetrahydrocannabinol (THC): Involvement of serotoninergic and dopaminergic pathways
52. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes
53. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
54. Anandamide hydrolysis by human cells in culture and brain
55. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells
56. Distribution of neuronal cannabinoid receptors in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization hystochemistry
57. Glucocorticold regulation of cannabinoid receptor messenger RNA levels in rat caudate-putamen. An in situ hybridation study
58. Activation of multiple transcription factor genes by D9-tetrahydrocannabinol in rat forebrain
59. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2
60. Paradoxical action of the cannabinoid WIN-55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
61. Pharmacological and biochemical interactions between opioids and cannabinoids
62. Discovery and characterization of endogenous cannabinoids
63. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
64. Search for endogenous ligands of the cannabinoid receptors
65. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptor
66. Effects of maternal D9-tetrahydrocannabinol on developing serotonergic system
67. Maternal exposure to D9-tetrahydrocannabinol affects indolamine levels and turnover in adult male and female rat brain regions
68. Molecular characterization of a peripheral receptor for cannabinoids
69. An acute dose of D9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity
70. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells
71. Antagonism of marihuana effects by indomethacin
72. Pharmacoly of cannabinoid CB1 and CB2 receptors
73. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neural non-CB1 cannabinoid receptors
74. A role for central cannabinoid and opioid systems in peripheral D9-tetrahydrocannabinol-induced analgesia in mice
75. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes
76. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
77. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
78. Down- regulation of rat brain cannabinoid binding sites after chronic D9-tetrahydrocannabinol treatment
79. Cannabinoid receptot in rat brain areas: Sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement
80. The putative cannabinoid receptor ligand, anandamide, stimulates hypothalamic tyrosine hydroxylase activity and inhibits prolactin release
81. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons
82. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function
83. Changes in rat brain cannabinoid binding sites after acute o chronic exposure to their endogenous agonist, anandamide or to D9-tetrahydrocannabinol
84. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand
85. Involvement of GABAB receptors in the motor inhibition produced by agonists of brain cannabinoid receptors
86. Effects of chronic exposure to D9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions
87. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake
88. Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation
89. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]-guanylyl-5'-O-(thio)-triphosphate binding in the basal ganglia of aged rats
90. Anandamide and WIN 55,212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes
91. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the D9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes
92. Nacylated glycerophospholipid and their derivatives
93. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
94. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
95. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
96. Anandamide- and D9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR 141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-1 Hpyrazole-3-carboximide hydrochloride]
97. Palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
98. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway
99. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microgila, and human monocytes
100. A second endogenous cannabinoid that modulates long-term potentiation
101. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
102. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
103. Evidence for a bidirectional cross-tolerance between morphine and D9-tetrahydrocannabinol in mice
104. Physical withdrawal in rats tolerant to D9-tetrahidrocannabinol precipitated by a cannabinoid receptor antagonist
105. Immunohistochemical distribution of cannabinoid-CB1 receptors in the rat central nervous system
106. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry
107. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons
108. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells
109. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
110. Perinatal exposure to D9-tetrahydrocannabinol (D9-THC) leads to changes in opioid-related behavioral patterns in rats
111. Isolation of fatty acid amide as an angiogenic principle from bovine mesentery
112. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide
113. Cannabinoid receptor binding and messenger RNA expression in human brain: An 'in vitro' receptor autoradiography and 'in situ' hybridation histochemistry study of normal aged and Alzheimer's brains
114. D9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats